LivaNova PLC Ordinary Shares (LIVN) — Analysis Summary
LivaNova PLC Ordinary Shares (LIVN) has a market cap of $4.26B with year-over-year revenue growth of +10.7%. Net margin stands at -17.5%. The stock trades at a P/E ratio of 22.6.
Key Takeaways
- Revenue changed +10.7% year-over-year
- Net margin of -17.5%
- P/E ratio of 22.6
Compared to other companies in the ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS sector, LIVN posted revenue growth of +10.7% and trades at a P/E of 22.6.
LivaNova PLC Ordinary Shares (LIVN)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives approximately half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
Sector
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Employees
3,300
Headquarters
GLOUCESTER
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.